Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.

ABSTRACT: Breast cancer brain metastases remain a significant clinical problem. Chemotherapy is ineffective and a lack of treatment options result in poor patient outcomes. Targeted therapeutics have proven to be highly effective in primary breast cancer, but lack of molecular genomic characterization of metastatic brain tumors is hindering the development of new treatment regimens. Here we contribute to fill this void by reporting on gene copy number variation (CNV) in 10 breast cancer metastatic brain tumors, assayed by array comparative genomic hybridization (aCGH). Results were compared to a list of cancer genes verified by others to influence cancer. Cancer gene aberrations were identified in all specimens and pathway-level analysis was applied to aggregate data, which identified stem cell plur

SUBMITTER: Bollig-Fischer A 

PROVIDER: S-EPMC4546491 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature